Minimal information about T cell assays: The process of reaching the community of T cell immunologists in cancer and beyond

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 15-22

  Britten, C M ^a,b   Janetzki, S ^c   Van Der Burg, S H ^d   Huber, C ^e   Kalos, M ^f   Levitsky, H I ^g   Maecker, H T ^h   Melief, C J M ^d   O'Donnell Tormey, J ⁱ   Odunsi, K ^j   Old, L J ^k   Pawelec, G ^l   Roep, B O ^d   Romero, P ^m   Hoos, A ⁿ   Davis, M M ^h  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b BIONTECH AG   (Germany)

^c ZellNet Consulting Inc   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Association for Cancer Immunotherapy (CIMT)   (Germany)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Institute of Cancer Research   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁿ BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Immune monitoring; MIATA; Minimal information about T cell assays; Reporting guidelines

Indexed keywords

AUTOIMMUNITY; CANCER IMMUNOLOGY; CELL ASSAY; CELLULAR IMMUNITY; CONSULTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE; WORKSHOP;

ALLERGY AND IMMUNOLOGY; CONSENSUS; HUMANS; IMMUNOLOGIC TECHNIQUES; MONITORING, PHYSIOLOGIC; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT; RESEARCH DESIGN; T-LYMPHOCYTES;

EID: 79953750263     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0940-z     Document Type: Review

References (32)

1. Goldman B, DeFrancesco L (2009) The cancer vaccine roller coaster. Nat Biotechnol 27(2):129-139. doi:10.1038/nbt0209-129
2. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A (2007) Lessons from randomized phase III studies with active cancer immunotherapies - outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 25(Suppl 2):B97-B109. doi:10.1016/j.vaccine.2007.06. 067 (Pubitemid 47488554)
3. Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, Winter JN, Flowers CR, Stergiou AM, Kwak LW, For the BiovaxID Phase III Study Investigators (2009) Idiotype vaccine therapy (biovaxid) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol 27:18s (Suppl; Abstr 2)
4. Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, Gailani F, Riley LB, Vena D, Hwu P (2009) A phase III multi-institutional randomized study of immunization with the gp100: 209-217 (210 m) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 27:18s
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. doi:10.1056/NEJMoa1003466
6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422. doi:10.1056/NEJMoa1001294
7. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L (2009) Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 15(4):1443-1451. doi:10.1158/1078-0432.CCR-08-1231
8. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838-1847. doi:10.1056/ NEJMoa0810097
9. Roep BO, Peakman M (2010) Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 10(2):145-152. doi:10.1038/nri2705
10. Kalos M (2010) An integrative paradigm to impart quality to correlative science. J Transl Med 8:26. doi:10.1186/1479-5876-8-26
11. Schloot NC, Meierhoff G, Karlsson Faresjo M, Ott P, Putnam A, Lehmann P, Gottlieb P, Roep BO, Peakman M, Tree T (2003) Comparison of cytokine elispot assay formats for the detection of islet antigen autoreactive t cells. Report of the third immunology of diabetes society t-cell workshop. J Autoimmun 21(4):365-376 (Pubitemid 37414931)
12. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57(3):303-315. doi:10.1007/s00262-007-0380-6 (Pubitemid 350295382)
13. Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P (2009) Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 58(10):1701-1713. doi:10.1007/s00262-009-0681-z
14. Hanekom WA, Dockrell HM, Ottenhoff TH, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ (2008) Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 5(7):e145. doi:101371/journal.pmed0050145
15. Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH, Dockrell HM, Mascart F (2009) Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One 4(11):e7972. doi:10.1371/journal.pone.0007972
16. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C et al (2008) The CIMT-monitoring panel: a twostep approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57(3):289-302. doi:10.1007/s00262-007-0378-0 (Pubitemid 350295380)
17. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJM, Old LJ, Romero P, Hoos A, Davis MM (2009) "MIATA"-minimal information about T cell assays. Immunity 31(19833080):527-528
18. The MIATA project (2010)http://miataproject.org/. Accessed September 24
19. Brazma A, Robinson A, Cameron G, Ashburner M (2000) Onestop shop for microarray data. Nature 403(6771):699-700. doi:10.1038/35001676
20. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C et al (2001) Minimum information about a microarray experiment (miame)-toward standards for microarray data. Nat Genet 29(4):365-371. doi:10.1038/ng1201- 365ng1201-365 (Pubitemid 34326681)
21. Taylor CF, Field D, Sansone S-A, Aerts J, Apweiler R, Ashburner M et al (2008) Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 26(18688244):889-896
22. Maecker HT, Nolan GP, Fathman CG (2010) New technologies for autoimmune disease monitoring. Curr Opin Endocrinol Diabetes Obes 17(4):322-328. doi:10.1097/MED.0b013e32833ada91
23. Ornatsky O, Bandura D, Baranov V, Nitz M, Winnik MA, Tanner S (2010) Highly multiparametric analysis by mass cytometry. J Immunol Methods. doi:10.1016/j.jim.2010.07.002
24. Davis MM (2008) A prescription for human immunology. Immunity 29(6):835-838. doi:10.1016/j.immuni.2008.12.003
25. Burgoon LD (2007) Clearing the standards landscape: the semantics of terminology and their impact on toxicogenomics. Toxicol Sci 99(2):403-412. doi:10.1093/toxsci/kfm108
26. Orchard S, Taylor CF (2009) Debunking minimum information myths: one hat need not fit all. Nat Biotechnol 25(4):171-172. doi:10.1016/j.nbt.2008.12.001
27. MIACA (minimum information about a cellular assay) (2010) http://sourceforge.net/projects/miaca/. Accessed September 24
28. Lee JA, Spidlen J, Boyce K, Cai J, Crosbie N, Dalphin M et al (2008) Miflowcyt: the minimum information about a flow cytometry experiment. Cytometry A 73(10):926-930. doi:10.1002/cyto.a.20623
29. Alvarez DF, Helm K, Degregori J, Roederer M, Majka SM (2009) Publishing flow cytometry data. Am J Physiol Lung Cell Mol Physiol. doi:10.1152/ajplung. 00313.2009
30. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (remark). J Natl Cancer Inst 97(16):1180-1184. doi:10.1093/jnci/dji237 (Pubitemid 41258223)
31. Mallett S, Timmer A, Sauerbrei W, Altman DG (2010) Reporting of prognostic studies of tumour markers: a review of published articles in relation to remark guidelines. Br J Cancer 102(1):173-180. doi:10.1038/sj.bjc.6605462
32. Mahnke Y, Chattopadhyay P, Roederer M (2010) Publication of optimized multicolor immunofluorescence panels. Cytometry A 77(9):814-818. doi:10.1002/cyto.a.20916